Israel - English - Ministry of Health

gilead sciences israel ltd - sofosbuvir - film coated tablets - sofosbuvir 400 mg - sofosbuvir - sovaldi is indicated in combination with other medicinal products for the treatment of chronic hepatitis c (chc) in adults.for hepatitis c virus (hcv) genotype specific activity, see physician leaflet .

Israel - English - Ministry of Health

gilead sciences israel ltd - sofosbuvir - film coated tablets - sofosbuvir 400 mg - sofosbuvir - sovaldi is indicated in combination with other medicinal products for the treatment of chronic hepatitis c (chc) in adults.for hepatitis c virus (hcv) genotype specific activity, see physician leaflet .

Israel - English - Ministry of Health

gilead sciences israel ltd - sofosbuvir - film coated tablets - sofosbuvir 400 mg - sofosbuvir - sovaldi is indicated in combination with other medicinal products for the treatment of chronic hepatitis c (chc) in adults.for hepatitis c virus (hcv) genotype specific activity, see physician leaflet .

Canada - English - Health Canada

criterion sciences - dextrose - liquid - 5g - dextrose 5g - diabetes mellitus

Canada - English - Health Canada

criterion sciences - dextrose - liquid - 10g - dextrose 10g - diabetes mellitus

Canada - English - Health Canada

criterion sciences - dextrose - liquid - 7.5g - dextrose 7.5g - diabetes mellitus

Australia - English - Department of Health (Therapeutic Goods Administration)

gilead sciences pty ltd - sofosbuvir -

United States - English - NLM (National Library of Medicine)

protein sciences corporation - influenza a virus a/michigan/45/2015 (h1n1) recombinant hemagglutinin antigen (unii: 69h0yj871t) (influenza a virus a/michigan/45/2015 (h1n1) recombinant hemagglutinin antigen - unii:69h0yj871t), influenza a virus a/hong kong/4801/2014 (h3n2) recombinant hemagglutinin antigen (unii: 2i1eol437m) (influenza a virus a/hong kong/4801/2014 (h3n2) recombinant hemagglutinin antigen - unii:2i1eol437m), influenza b virus b/brisbane/60/2008 recombinant hemagglutinin antigen (unii: 058u2312cr) (influenza b virus b/bri - influenza a virus a/michigan/45/2015 (h1n1) recombinant hemagglutinin antigen 45 ug in 0.5 ml - flublok is a vaccine indicated for active immunization against disease caused by influenza a virus subtypes and influenza type b virus contained in the vaccine. flublok is approved for use in persons 18 years of age and older. flublok is contraindicated in individuals with known severe allergic reactions (e.g., anaphylaxis) to any component of the vaccine (see postmarketing experience [6.2] and description [11] ). pregnancy outcomes in women who have been exposed to flublok during pregnancy are being monitored. contact: protein sciences corporation by calling 1-888-855-7871. all pregnancies have a risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risks of major birth defects and miscarriage in clinically recognized pregnancies are 2% to 4% and 15% to 20%, respectively. available data on flublok administered to pregnant women are insufficient to inform vaccine-associated risks in pregnant women. a developmental study of flublok has been performed in

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

gilead sciences international ltd - sofosbuvir - tablet - 400mg